Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
about
Hepatitis C virus protease inhibitor-resistance mutations: our experience and reviewMaximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virusSelection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C VirusGeneral Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide AnaloguesEvolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In VitroBinding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsActivity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee ModelPhenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine ProteaseIn Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseRelative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemDiscovery and Characterization of Substituted Diphenyl Heterocyclic Compounds as Potent and Selective Inhibitors of Hepatitis C Virus ReplicationSelection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase InhibitorsDevelopment of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase InhibitorsSelected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R14791,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside InhibitorsNaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsPreclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseSlow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C VirusHepatitis C: recent successes and continuing challenges in the development of improved treatment modalitiesPhenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alphaNaturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b.What to do if standard therapy for hepatitis C fails.Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitorsHepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antiviralsInhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.Resistance mechanisms in HCV: from evolution to intervention.Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.A small molecule inhibits HCV replication and alters NS4B's subcellular distribution.Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.
P2860
Q24628717-682441A1-6667-432F-B314-73F743A43031Q26830190-32753C21-C866-4886-9B09-B18092F3A304Q27473236-EE683F39-E57C-4158-A3D6-EAE8264BEB7BQ27477760-640C2973-E8AF-4898-8B6A-F4B4BA4278B4Q27480267-975D58EA-B6CE-4A6F-993F-2A3B9216A79AQ27480361-3476B9F9-5947-4559-A56E-3396FB3BFC58Q27480926-2EF83D9A-54BC-492B-B14B-DEA615048EB2Q27484513-40839F2F-1167-4BD3-AAEF-6D1B5347ADB1Q27485288-9C4BE614-0FEB-4EB6-BDD6-F4DCB2D1B1CAQ27485335-0E94F0B8-761E-4B75-B468-A28DE2CBC2CFQ27485441-CD91FD15-88EA-4E24-9317-3BCCB2335512Q27485724-FC41EA3F-0F91-427D-B3D9-8999803CB762Q27486249-E7290C26-29B3-4CD8-8450-84942AC5077DQ27487022-40224D89-CB25-4C95-948C-FF099DBA76ABQ27487389-BBA26FD4-94EC-4C5D-8080-4F37CE84BE60Q27487390-84CC817E-8AAE-4B8F-8761-16CC44C55011Q27487949-483109B5-9832-4659-BD82-BD0EE3E430A8Q27488428-5A2DA3B4-E28E-42A9-825F-8E89651A3852Q27488887-E08F8D6C-516B-42E4-A90D-F70CA022FCA8Q27490426-7C740FD6-5C10-4D8E-9B1B-6DD1AB05EA3DQ27645411-E9E96C03-E909-436A-862B-4D77A6FAD492Q31149778-9F7054A1-2851-4F4F-B2E4-B9C621A24C62Q33568807-6DB02BD8-D520-4B8B-A0F6-C410978EFAF3Q34530512-FF2A5C96-D033-4A68-A7D5-FDF3DD119055Q34957256-5A984088-6542-4931-9FBE-B4DBA72D3CDFQ35064369-8594BAFE-17E0-4E96-9E92-DE646A292858Q35565927-6212853E-4BFB-458B-BE1F-5A266D06BCCEQ36841724-2891C842-47F6-46FA-A3A9-5E73726EDF44Q37228736-DF9C73B6-A944-4818-9B99-B660AA07E301Q37313166-BC16AFF1-AACD-4B2F-992B-06666BC5B6FAQ37540618-F0CA233B-6E07-42ED-901E-0A369C6EEC8BQ37939247-FB60B789-9D53-415E-A823-5FD965FB4703Q37990840-51AE4D3C-B2FD-4720-B3F2-C5CBC971251FQ38034733-E0B6FCEA-6C3D-4C11-ABC5-B04752D9C81BQ38283097-EACAE5B1-5F9F-4088-B8DB-D73AD864DE7BQ38283239-6CBC63CC-400D-4A5A-A3F6-2D183AADA00AQ38284922-F3C8AD48-845A-4CE6-9E19-9F4822B9D201Q38864459-BC4D4E08-B130-4B27-AD4D-1FB66CFB215CQ38934649-539C778C-104A-402F-A7A4-A9FF897E9304Q39470512-18D82B7F-10F5-4A67-B961-F1C06E376162
P2860
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mutations Conferring Resistanc ...... ne Protease Inhibitor In Vitro
@nl
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@ast
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@en
type
label
Mutations Conferring Resistanc ...... ne Protease Inhibitor In Vitro
@nl
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@ast
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@en
prefLabel
Mutations Conferring Resistanc ...... ne Protease Inhibitor In Vitro
@nl
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@ast
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@en
P2093
P2860
P50
P1476
Mutations conferring resistanc ...... e protease inhibitor in vitro.
@en
P2093
Akhteruzzaman Molla
Clarence Maring
Gennadiy Koev
Hongmei Mo
John Pratt
Liangjun Lu
Pam Donner
Ron Pithawalla
Rubina Mondal
Sherie Masse
P2860
P304
P356
10.1128/AAC.49.10.4305-4314.2005
P407
P577
2005-10-01T00:00:00Z